Company intelligence / Profile preview

Allurion

Natick, Massachusetts, United Statesallurion.com ↗

Ownership: Public · ALUR
Employees: ~117
Development stage: Other

Overview

Allurion has commercialized a swallowable, procedure-less gastric balloon for weight loss that does not require surgery or endoscopy. The program combines this device with a digital health suite for patient monitoring and behavioral support. Over 100,000 patients have been treated globally. Clinical data show average total body weight loss of about 10–15% over four months. Combination trials with GLP‑1 agonists are ongoing to improve long-term outcomes and tolerability of pharmacotherapy.[1][4][5][7][8]

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: Device (swallowable gastric balloon)Digital health platform (AI-powered virtual care suite)Small molecule (GLP‑1 agonists in combination studies)
Industry: Therapeutic Medical Devices

Partnerships

MedtronicRTW Investments

Beyond the preview

Go deeper on Allurion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allurion.

Explore the full profile